Abstract
Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.
Original language | English (US) |
---|---|
Pages (from-to) | 713-733 |
Number of pages | 21 |
Journal | Cytotherapy |
Volume | 16 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2014 |
Keywords
- Cancer treatment
- CAR T cells
- Genetic modification of T cells
- Immunotherapy
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
- Oncology
- Genetics(clinical)
- Transplantation
- Cancer Research
- Cell Biology